---
title: "Akums Drugs & Pharmaceuticals Ltd (AKUMS) — Share Price, Financials & Analysis"
symbol: "AKUMS"
company: "Akums Drugs & Pharmaceuticals Ltd"
canonical: "https://tapetide.com/stocks/AKUMS"
isin: "INE09XN01023"
nse_symbol: "AKUMS"
bse_code: "544222"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 11781.73
generated_at: "2026-09-13T19:06:48.633Z"
---

# Akums Drugs & Pharmaceuticals Ltd (AKUMS)

Canonical page: https://tapetide.com/stocks/AKUMS

## Company

- **NSE Symbol:** AKUMS
- **BSE Code:** 544222
- **ISIN:** INE09XN01023
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2024-08-06
- **CEO:** Mr. Sanjeev Jain
- **Employees:** 7536
- **Face Value:** ₹2
- **F&O Eligible:** No
- **Website:** akums.in

## About

Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.[1]

## Latest Price

- **Price:** ₹776.35
- **Change:** +26.7 (+3.56%)
- **Open:** ₹753
- **Day High:** ₹784.4
- **Day Low:** ₹740.5
- **Previous Close:** ₹749.65
- **Volume:** 398725
- **As Of:** 2026-09-11T10:27:05+00:00

## Key Fundamentals

Observed at 2026-09-11T04:37:17.571487Z.

- **Market Cap:** ₹11781.73 Cr
- **Classification:** Microcap
- **P/E (reported):** 40.3
- **P/E (TTM):** 41.9
- **EPS (TTM):** ₹18.53
- **EPS (reported):** ₹0
- **Book Value:** ₹210.57
- **Price to Book:** 3.56
- **Dividend Yield:** 0.4%
- **ROE:** 7.7%
- **ROCE:** 10.94%
- **Debt to Equity:** 0.05
- **Revenue (yearly):** ₹4487.7 Cr
- **Net Income:** ₹256.4 Cr
- **EBITDA:** ₹650.7 Cr
- **52-Week High:** ₹796.55
- **52-Week Low:** ₹409.3
- **RSI (14):** 52.98

## Tapetide Score

- **Score:** 54 / 100
- **Score date:** 2026-09-04
- **Archetype:** Cheap but Weak
- **What it means:** A low multiple sitting on weak financials. Worth establishing what the market is discounting before treating the low valuation as an opportunity — weak fundamentals often justify it.
- **Pillar profile:** Quality: Weak · Valuation: Cheap · Momentum: Rising
- **Percentile:** 65.6 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 43.03 | 9% |
| growth | 31.89 | 9% |
| momentum | 85.71 | 12% |
| ownership | 46.57 | 24% |
| quality | 44.79 | 22% |
| valuation | 67.44 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is almost debt free.

### Weaknesses

- Stock is trading at 3.69 times its book value
- The company has delivered a poor sales growth of 9.87% over past five years.
- Company has a low return on equity of 9.89% over last 3 years.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 153.91% | 137.06% | — |
| ebitda margin growth | 10.75% | 17.03% | 288.74% | -875.4% |
| net income growth | 24.23% | -25.42% | 29% | 16% |
| revenue growth | 0.32% | 7.61% | 6% | 10% |
| roce | 13.02% | -7.29% | — | 4.59% |
| roe | 24.15% | -31.37% | 6.34% | -119.19% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 1181 | 1083 | 944 | 1019 | 1033 | 1010 | 1056 | 1024 | 1018 | 1160 | 1158 | 1167 |
| Expenses | 1029 | 989 | 941 | 891 | 912 | 889 | 962 | 895 | 923 | 1013 | 1006 | 992 |
| Operating Profit | 152 | 93 | 3 | 128 | 121 | 121 | 94 | 129 | 94 | 147 | 152 | 175 |
| OPM % | 13 | 9 | 0.3 | 13 | 12 | 12 | 9 | 13 | 9 | 13 | 13 | 15 |
| Other Income | -21 | 10 | 10 | 7 | 17 | 19 | 26 | 27 | 32 | 16 | 34 | 30 |
| Interest | 14 | 12 | 12 | 13 | 12 | 5 | 5 | 23 | 23 | 24 | 24 | 25 |
| Depreciation | 30 | 32 | 34 | 34 | 35 | 45 | 40 | 37 | 38 | 40 | 40 | 41 |
| Profit before tax | 87 | 59 | -33 | 87 | 92 | 91 | 75 | 96 | 66 | 100 | 121 | 139 |
| Tax % | 62 | -229 | 20 | 30 | 27 | 27 | -99 | 32 | 35 | 32 | 33 | 27 |
| Net Profit | 33 | 195 | -39 | 61 | 67 | 66 | 150 | 65 | 43 | 68 | 81 | 101 |
| EPS in Rs | 2.22 | 13.54 | -2.89 | 4.08 | 4.14 | 4.14 | 9.38 | 4.03 | 2.59 | 4.21 | 5.38 | 6.35 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 1464 | 1651 | 2414 | 2723 | 3672 | 3655 | 4178 | 4118 | 4359 | 4502 |
| Expenses | 1340 | 1507 | 2240 | 2485 | 3761 | 3361 | 4055 | 3654 | 3837 | 3934 |
| Operating Profit | 124 | 144 | 174 | 238 | -89 | 294 | 123 | 465 | 522 | 568 |
| OPM % | 8 | 9 | 7 | 9 | -2.4 | 8 | 3 | 11 | 12 | 13 |
| Other Income | 6 | 6 | 26 | 11 | 7 | 15 | 8 | 69 | 108 | 112 |
| Interest | 23 | 22 | 20 | 7 | 17 | 46 | 51 | 35 | 94 | 96 |
| Depreciation | 31 | 38 | 67 | 70 | 95 | 113 | 126 | 153 | 155 | 159 |
| Profit before tax | 77 | 89 | 114 | 172 | -193 | 150 | -45 | 345 | 382 | 426 |
| Tax % | 51 | 50 | 62 | 28 | 30 | 35 | -102 | 0 | 33 | — |
| Net Profit | 43 | 61 | 44 | 123 | -251 | 98 | 1 | 344 | 256 | 293 |
| EPS in Rs | 366.55 | 523.23 | 335.61 | 943.49 | -35.3 | 6.63 | -0.28 | 21.49 | 16.21 | 18.53 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 1 | 1 | 1 | 1 | 14 | 29 | 29 | 31 | 31 |
| Reserves | 493 | 628 | 721 | 884 | 608 | 689 | 681 | 3016 | 3283 |
| Borrowings | 255 | 213 | 175 | 130 | 395 | 619 | 565 | 88 | 157 |
| Other Liabilities | 293 | 318 | 1140 | 1137 | 2033 | 1905 | 2229 | 960 | 1958 |
| Total Liabilities | 1042 | 1161 | 2037 | 2152 | 3050 | 3241 | 3504 | 4095 | 5429 |
| Fixed Assets | 444 | 501 | 645 | 904 | 1021 | 1097 | 1191 | 1397 | 1456 |
| CWIP | 0 | 11 | 57 | 17 | 31 | 103 | 195 | 163 | 177 |
| Investments | 0 | 18 | 6 | 20 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 598 | 632 | 1329 | 1212 | 1998 | 2041 | 2118 | 2535 | 3796 |
| Total Assets | 1042 | 1161 | 2037 | 2152 | 3050 | 3241 | 3504 | 4095 | 5429 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 72 | 89 | 28 | 131 | 32 | 177 | 498 | 465 | 1181 |
| Cash from Investing Activity | -150 | -123 | -190 | -109 | -235 | -305 | -331 | -548 | -930 |
| Cash from Financing Activity | 66 | 37 | 233 | -91 | 236 | 125 | -108 | 73 | 34 |
| Net Cash Flow | -11 | 4 | 71 | -70 | 33 | -4 | 59 | -10 | 285 |
| Free Cash Flow | -78 | -34 | -34 | 49 | -224 | -110 | 212 | 201 | 958 |
| CFO/OP | 72 | 98 | 44 | 74 | -98 | 93 | 455 | 118 | 243 |

### Ratios

| Item | Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 68 | 57 | 88 | 71 | 88 | 84 | 73 | 68 | 67 |
| Inventory Days | 114 | 115 | 99 | 93 | 112 | 117 | 90 | 102 | 110 |
| Days Payable | 67 | 60 | 105 | 74 | 92 | 91 | 76 | 96 | 87 |
| Cash Conversion Cycle | 115 | 112 | 82 | 90 | 109 | 111 | 87 | 74 | 89 |
| Working Capital Days | 78 | 73 | 55 | 66 | 49 | 46 | 40 | 71 | 66 |
| ROCE % | — | 14 | — | 20 | -16 | 22 | 2 | 16 | 15 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% |
| FIIs | 7.34% | 6.36% | 5.77% | 4.24% | 2.28% | 1.15% | 1.37% | 1.91% |
| DIIs | 7.52% | 7% | 7.4% | 8.85% | 9.28% | 14.4% | 14.35% | 13.44% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 2.11% | 3.33% | 3.41% | 3.6% | 5.01% | 5.51% | 5.34% | 5.57% |
| Others | 7.77% | 8.05% | 8.16% | 8.05% | 8.18% | 3.68% | 3.68% | 3.82% |
| No. of Shareholders | 57531 | 68410 | 69366 | 69424 | 75365 | 76869 | 72589 | 70289 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 12 / 6 / 1

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 763.07 | Buy |
| EMA (10) | 758.78 | Buy |
| SMA (20) | 759.52 | Buy |
| EMA (20) | 751.76 | Buy |
| SMA (50) | 714.99 | Buy |
| EMA (50) | 712.89 | Buy |
| SMA (100) | 638.58 | Buy |
| EMA (100) | 656.19 | Buy |
| SMA (200) | 549.35 | Buy |
| EMA (200) | 596 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 60.3 | Neutral |
| MACD (12,26,9) | 13.31 | Sell |
| Stochastic (14,3,3) | 35.57 | Neutral |
| ADX (14) | 37.19 | Buy |
| Williams %R (14) | -31.86 | Neutral |
| ATR (14) | 27.06 | High Volatility |
| ROC (12) | 1.34 | Buy |
| Stoch RSI (14) | 66.57 | Neutral |
| UO (7,14,28) | 44.37 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 3 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |

Based on 3 analyst ratings, observed at 2026-09-11T04:37:17.465521+00:00.

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-03 | [ESG Rating](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8522709b-2f49-4427-95a4-98fc451fe51b.pdf) |
| 2026-08-25 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9b0f1271-56ec-412a-a7df-7189d27553c1.pdf) |
| 2026-08-24 | [Update On Schedule Of The Investors/Analysts Meet To Be Held On August 25 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=73dea697-4bca-4319-a4e5-a1383764767f.pdf) |
| 2026-08-13 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8ac8c7a1-558d-473e-95fd-8732d7b037a3.pdf) |
| 2026-08-10 | [Monitoring Agency Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1691cbe7-b072-40f9-9885-28ea6c4d39f4.pdf) |
| 2026-08-10 | [Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=98f4b10c-4cdb-4669-b39e-0b5a390d2439.pdf) |
| 2026-08-10 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1473f148-97e6-4fd3-be56-ff416a4c42be.pdf) |
| 2026-08-08 | [Board Meeting Outcome for Un-Audited Financial Results For The Quarter Ended 30Th June 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ac0e265e-d06f-4040-bb92-b97e9ca548dc.pdf) |
| 2026-08-08 | [Press Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=db415f10-c935-4ebf-80b6-a0c7f0ddbc01.pdf) |
| 2026-08-05 | [Board Meeting Intimation for Un-Audited (Standalone & Consolidated) Financial Results For The Quarter Ended On 30Th June 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4111569b-bdad-47ca-a21e-dd91c7c7ee1f.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-13 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e9074cac-f649-4e42-9344-02f6296ffc48.pdf) |
| 2026-05-21 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f1abc49d-9839-4a87-87ad-e491ad151912.pdf) |
| 2026-02-19 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fc95a6bd-88bb-43ad-874d-8ed8c4569212.pdf) |
| 2025-11-17 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5658bd77-1973-45dd-be8a-50cb2923cf98.pdf) |
| 2025-08-18 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=85563c52-9ce2-48a7-b5a1-788d7d91dd2c.pdf) |
| 2025-06-02 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=73ca08f4-cba0-4b93-8099-1647985115ff.pdf) |
| 2025-02-11 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=04e92c90-c85a-4a05-a977-b1807341f051.pdf) |
| 2024-11-15 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0c1f16ad-4a86-41c2-816f-0f5cb26d3969.pdf) |
| 2024-09-04 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e8c6d8cc-2e2f-4d10-ba25-e0eda6a6e6c8.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-08-10 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f98b4d67-b5dd-4634-b41f-d1b33632e3e6.pdf) |
| 2026-05-18 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=431247e7-93d8-4257-bb53-452cfc3031e7.pdf) |
| 2026-02-16 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=174cb1ad-3a09-4f72-b06b-d3f46c9cfd17.pdf) |
| 2025-11-14 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b405e872-2812-48d6-b90f-4a2c921030ab.pdf) |
| 2025-08-11 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5a2dd48b-6f16-4f82-8250-6d72bf8c5509.pdf) |
| 2025-05-27 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b4bccd9a-1717-4462-9655-f24287b453b6.pdf) |
| 2024-11-11 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=715d938f-93a8-4ea4-a002-121426a76969.pdf) |
| 2024-08-30 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0d36fbdd-7d78-4273-8c35-36b8c5da194b.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-08 | [Un-Audited Financial Results For The Quarter Ended 30Th June 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d923ee47-d806-4f03-9dbc-1e1ffdf1f6ab.pdf) |
| 2026-05-14 | [Financial Results For The Quarter And Year Ended 31St March 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1a5e3be8-49f0-4e34-83cf-d45500c1c1c7.pdf) |
| 2026-02-13 | [Approval Of Un-Audited Financial Results For The Quarter And Nine Months Ended 31.12.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ce7e4052-a319-4875-8696-fd0b76fbe23a.pdf) |
| 2025-11-13 | [Outcome Of Board Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c642fd82-772b-4a9a-b46c-c1d3ef4fd909.pdf) |
| 2025-08-08 | [Outcome Along With Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4a247694-4f14-4fde-a31f-24a5236565a1.pdf) |
| 2025-05-26 | [Outcome Of Board Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d2a43301-b3a5-48a7-b89f-f4250f9699a1.pdf) |
| 2025-02-07 | [Un-Audited Financial Results For The Quarter And Nine Months Ended December 31 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=415df990-b404-44f6-adf0-1d1fc360f7a9.pdf) |
| 2024-11-09 | [Outcome Of Board Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e6df8f92-d218-4919-988d-090b53fe59a8.pdf) |
| 2024-08-24 | [Un-Audited Financial Results For The Quarter Ended 30.06.2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a555cb29-2fc7-4979-a318-165a5cc23aae.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-08-08 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7dbc7351-a63c-41b0-bc54-b0fe0dc4703d.pdf) |
| 2026-05-14 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=33037234-0d21-42b8-a5cb-5a75091dc3e9.pdf) |
| 2026-02-13 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4ea4417e-06c8-48f5-a21d-26289582b859.pdf) |
| 2025-11-13 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=db6e9ff1-303d-411e-ba00-d9a91ec47848.pdf) |
| 2025-08-08 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=44e60f7d-f557-4681-a14e-aad6f34bbd40.pdf) |
| 2025-05-26 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8a5fafd3-6197-42ae-bcd1-c2d645b1ec85.pdf) |
| 2025-02-07 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3e70b43f-7196-4d98-b111-09c719148a9b.pdf) |
| 2024-11-09 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=863d323c-702b-4285-92f0-ec8197722fa3.pdf) |
| 2024-08-24 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f8da9129-1e42-4429-bc45-bb6f88395d2c.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 8 May - Akums received unsolicited ESG rating of 63 for FY2024-25 from NSE Sustainability on 7 May 2026. | [ESG Rating 8 May - Akums received unsolicited ESG rating of 63 for FY2024-25 from NSE Sustainability on 7 May 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/edab309a-d805-463e-ae2c-60a21ea05c5f.pdf) |
| 5 Feb - USFDA EIR closes Chestnut Ridge inspection (Dec 17–23, 2025), classified VAI; supports nasal spray pre-approval. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 5 Feb - USFDA EIR closes Chestnut Ridge inspection (Dec 17–23, 2025), classified VAI; supports nasal spray pre-approval.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f9e8191a-4aa7-470b-88b3-ab4f0f7db8cc.pdf) |
| 5 Feb - USFDA closed Chestnut Ridge inspection (Dec 17-23, 2025) as VAI; covered drug-device nasal sprays. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised) 5 Feb - USFDA closed Chestnut Ridge inspection (Dec 17-23, 2025) as VAI; covered drug-device nasal sprays.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/258bbc32-e404-4002-894b-82ba273a4c59.pdf) |
| 4h - Board meets May 14, 2026 to approve FY26 audited results and consider dividend. | [Board Meeting Intimation for Board Meeting Intimation 4h - Board meets May 14, 2026 to approve FY26 audited results and consider dividend.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/e48608e0-af71-44eb-a3f4-3e70e297cbc8.pdf) |
| 4 Feb - Strides to meet investors at Manthan Systematix on Feb 10, 2026 to discuss Q3 FY26 earnings presentation. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 4 Feb - Strides to meet investors at Manthan Systematix on Feb 10, 2026 to discuss Q3 FY26 earnings presentation.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7ced99df-34a6-40a9-83b5-2b56b7e6bbfc.pdf) |
| 4 Apr - Regulation 74(5) compliance certificate received for quarter ended 31 March 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 4 Apr - Regulation 74(5) compliance certificate received for quarter ended 31 March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/32e680de-ee59-4402-856c-9783b36f9a36.pdf) |
| 3 Feb - Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025. | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript 3 Feb - Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cc699e4f-05b6-40ff-90e4-86189ee75d00.pdf) |
| 29 Apr - Pure and Cure Healthcare leased 4,050 sq. m industrial plot at Haridwar on April 28, 2026. | [Execution Of Lease Deed 29 Apr - Pure and Cure Healthcare leased 4,050 sq. m industrial plot at Haridwar on April 28, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/454c5f49-18ff-46c2-b3fe-a75793be7cb9.pdf) |
| 29 Apr - Pure and Cure Healthcare leased 4,050 sq. m industrial plot at Haridwar on April 28, 2026. | [Execution Of Lease Deed 29 Apr - Pure and Cure Healthcare leased 4,050 sq. m industrial plot at Haridwar on April 28, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/454c5f49-18ff-46c2-b3fe-a75793be7cb9.pdf) |
| 26 Feb - Akums to attend Bharat Connect Conference on 10 March 2026 (virtual); no UPSI to be shared. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 26 Feb - Akums to attend Bharat Connect Conference on 10 March 2026 (virtual); no UPSI to be shared.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8654a660-f6a7-4110-a54d-a51ec48191a2.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Sep 2024 | [Concall - Sep 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e8c6d8cc-2e2f-4d10-ba25-e0eda6a6e6c8.pdf) |
| Oct 2024 | [Concall - Oct 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5f3d350e-e9b9-41a3-96ce-a21a51d77b3e.pdf) |
| Oct 2024 | [Concall - Oct 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/432ef4b9-4063-41ee-b37e-598a22ab489f.pdf) |
| Oct 2023 | [Concall - Oct 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b9b95a97-0bd9-44c8-94ea-cf40759e821d.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/db6e9ff1-303d-411e-ba00-d9a91ec47848.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5658bd77-1973-45dd-be8a-50cb2923cf98.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/bb389025-5ce3-44c1-8940-cfd76882df76.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0c1f16ad-4a86-41c2-816f-0f5cb26d3969.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ae220251-3a15-4d0c-8e95-b004dbd3c98c.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4cff21ee-b329-4f1d-bc05-9e9607d6fbe2.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/40c769ef-bb37-46e6-a96d-e95b55734c3a.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fbd8d121-b061-4a6c-a8da-ee67103258de.pdf) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7591369b-b3bf-458a-9e6e-710f89f6bd4b.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f3fef37a-74ee-491f-87fe-2e2cc48005a0.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2849f7f9-46e1-4ecb-a836-986717170dcb.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/532531/74399532531.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/532531/69463532531.pdf) |
| from bse | [Financial Year 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/532531/5325310320.pdf) |
| from bse | [Financial Year 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/532531/5325310319.pdf) |
| from bse | [Financial Year 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/532531/5325310318.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:06:48.633Z.